Core Viewpoint - BBSB INTL, a civil engineering contractor, has successfully completed its IPO with significant oversubscription, indicating strong investor interest and confidence in the company's growth potential in the Malaysian civil engineering sector [1] Group 1: IPO Details - BBSB INTL's IPO took place from December 31, 2025, to January 8, 2026, with a total of HKD 778.7 billion in margin loans secured by brokers, leading to an oversubscription of 8,898 times [1] - The company plans to issue 130 million shares, with 10% allocated for public offering and 90% for placement, at a price range of HKD 0.6 to 0.7 per share, aiming to raise up to HKD 87.5 million [1] - The expected listing date on the Hong Kong Stock Exchange's Growth Enterprise Market is January 13, 2026, with the exclusive sponsor being Lihua Enterprise Financing Limited [1] Group 2: Company Background and Market Position - BBSB INTL has over 16 years of experience in the Malaysian civil engineering sector, primarily providing bridge engineering services for large-scale transportation infrastructure projects initiated by the Malaysian government or its affiliates [1][2] - The company has expanded its service offerings to include flood control engineering, leveraging its existing expertise in bridge engineering [2] - BBSB INTL holds the highest contractor licenses (G7 level) from the Construction Industry Development Board of Malaysia, allowing it to undertake unlimited contract values in civil and structural engineering [2] Group 3: Financial Performance - For the fiscal years 2023 and 2024, BBSB INTL reported revenues of approximately MYR 76.8 million and MYR 133 million, respectively, with a net loss of MYR 14.5 million in 2023, followed by net profits of MYR 26.2 million in 2024 [2] - In the first six months of 2024 and 2025, the company achieved revenues of MYR 69.8 million and MYR 74 million, respectively, with net profits of MYR 1.21 million and MYR 0.32 million [2] Group 4: Use of IPO Proceeds - Approximately 65.2% of the net proceeds from the IPO will be used to strengthen the company's financial position, 19.8% for expanding workforce to support regional growth, 5% for upgrading information systems and internal processes, and 10% for general working capital [3]

Group 1 - The core viewpoint of the articles highlights the significant oversubscription of Changfeng Pharmaceutical's IPO, with a margin loan of at least HKD 339.6 billion and an oversubscription rate of 5,587 times, making it the second highest in the new stock market since the revised pricing mechanism was implemented [1][2] - Changfeng Pharmaceutical plans to globally offer 41.198 million H-shares, with 10% allocated for Hong Kong and 90% for international sales, at a price of HKD 14.75 per share, with trading expected to commence on October 8, 2025 [1] - The company specializes in the research, production, and commercialization of inhalation technology and drugs, focusing on respiratory diseases, and has received six product approvals from the National Medical Products Administration and the FDA, demonstrating its capabilities in clinical development and commercialization [1] Group 2 - Financially, Changfeng Pharmaceutical's revenue is projected to grow from RMB 349 million in 2022 to RMB 608 million in 2024, reflecting a compound annual growth rate of 31.9%, with gross profit expected to reach RMB 491 million, a year-on-year increase of approximately 7.2% [2] - The company benefits from operational efficiency due to economies of scale and aims to continue controlling administrative expenses, with the proportion of administrative costs to revenue expected to decline as the business expands [2]

Core Viewpoint - China Silver Group announced a financing plan through the issuance of 460 million new shares, raising approximately HKD 210 million, with a subscription price of HKD 0.45 per share, reflecting a discount compared to recent trading prices [1] Group 1: Financing Details - The company will issue 460,000,000 shares, raising about HKD 210 million after expenses [1] - The subscription price of HKD 0.45 represents a discount of approximately 1.32% compared to the average closing price of HKD 0.456 over the last five trading days prior to the subscription agreement [1] - The shares represent about 19.64% of the existing issued share capital and will account for approximately 16.42% of the enlarged share capital after completion [1] Group 2: Use of Proceeds - Approximately HKD 120 million will be allocated for purchasing inventory materials for the manufacturing segment [1] - About HKD 41.3 million will be used for exploration activities at the Shigatse mine and other potential mining opportunities [1] - Another HKD 41.3 million will be designated for general working capital of the group [1] Group 3: Company Overview - China Silver Group is a leading comprehensive enterprise in the silver and precious metals industry in China, involved in the manufacturing, sales, and trading of silver ingots, palladium, and jewelry products [1]

Subscription Details - Subscription deadline for non-loan applications is June 26, 2025, at 12:00 PM[3] - Results announcement date is July 2, 2025[3] - Refund date is July 3, 2025[3] - Listing date is July 3, 2025[3] - Subscription fee for new shares is HKD 100.00[3] Application Requirements - Clients must deposit the full subscription amount in their securities account by the deadline to qualify for subscription[6] - Late deposits or insufficient amounts may result in cancellation of the subscription application[6] - This material is based on the issuer's documents and does not constitute a recommendation from the company[6]